(S)-Reticuline

(S)-Reticuline

SCHEMBL147597

COc1ccc(C[C@H]2c3cc(O)c(OC)cc3CCN2C)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 1.00
DRD1 P21728 1/20 1.00
BCHE P06276 1/20 0.82
ACHE P22303 1/20 0.82
KCNH2 Q12809 2/20 0.77
LMNA P02545 2/20 0.76
KDM4E B2RXH2 2/20 0.76
ALDH1A1 P00352 2/20 0.76
HSD17B10 Q99714 2/20 0.76
MAPK1 P28482 1/20 0.76
CYP2D6 P10635 1/20 0.76
ALOX15 P16050 1/20 0.71
DRD4 P21917 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(R)-Reticuline SCHEMBL29373552 1.00 DRD2 (1.00) DRD2DRD1BCHEACHEKCNH2
(S)-Reticuline SCHEMBL147596 1.00 DRD2 (1.00) DRD2DRD1BCHEACHEKCNH2
(R)-Reticuline SCHEMBL29364903 1.00 DRD2 (1.00) DRD2DRD1BCHEACHEKCNH2
(R)-Reticuline SCHEMBL9587509 1.00 DRD2 (1.00) DRD2DRD1BCHEACHEKCNH2
(S)-Reticuline SCHEMBL29923953 1.00 DRD2 (1.00) DRD2DRD1BCHEACHEKCNH2
Laudanidine SCHEMBL18187574 0.98 DRD2 (0.95) DRD2DRD1BCHEACHEKCNH2
Codamine SCHEMBL15696578 0.95 DRD2 (0.91) DRD2DRD1BCHEACHEKCNH2
Codamine SCHEMBL680513 0.95 DRD2 (0.91) DRD2DRD1BCHEACHEKCNH2
Laudanidine SCHEMBL15696580 0.95 DRD2 (0.91) DRD2DRD1BCHEACHEKCNH2
Codamine SCHEMBL30720053 0.95 DRD2 (0.91) DRD2DRD1BCHEACHEKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1098 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388939-A1 RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF RIVER STONE BIOTECH APS (DK) 2025-12-25 US claimed
US-12497638-B2 Methods of producing epimerases and benzylisoquinoline alkaloids THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-12-16 US claimed
EP-4615963-A1 GENETICALLY MODIFIED BENZYLISOQUINOLINE ALKALOID-PRODUCING HOST CELLS WITH MODIFIED EFFLUX TRANSPORTER GENE EXPRESSION River Stone Biotech ApS (DK) 2025-09-17 EP claimed
US-12371722-B2 Recombinant host cells with improved production of L-DOPA, dopamine, S-noroclaurine or derivatives thereof RIVER STONE BIOTECH APS (DK) 2025-07-29 US claimed
US-12359233-B2 Production method of (R)-reticuline FERMELANTA, INC. (JP) 2025-07-15 US claimed
CN-119709674-A Berberine bridge enzyme mutant and application thereof in synthesis of (S) -scolerine 江南大学 2025-03-28 CN claimed
CN-119570825-A Method for efficiently synthesizing protoberberine compounds and application thereof 中国科学院分子植物科学卓越创新中心 2025-03-07 CN claimed
WO-2025031833-A1 RECOMBINANT STRAIN AND USE THEREOF IN PRODUCTION OF SCOULERINE CHRYSEA LIMITED (IE) 2025-02-13 WO claimed
WO-2024194018-A1 METHOD FOR PRODUCING CORYTUBERINE AND SALUTARIDINE Universität Graz (AT) 2024-09-26 WO claimed
EP-4431612-A1 PROCESS FOR THE PREPARATION OF CORORYLOURIN AND SALUTARIDINE Universität Graz (AT) 2024-09-18 EP claimed
WO-1997014713-A1 AMPHIPHILIC COMPLEXES, METHOD FOR PREPARING SAME AND COMPOSITIONS CONTAINING SUCH COMPLEXES COLETICA (FR) 1997-04-24 WO claimed
EP-0461201-B1 PROSTHETIC MENISCUS REGEN BIOLOG INC (US) 1995-07-26 EP claimed
EP-0638104-A1 UNDECYLENIC ACID DERIVATIVES WITH HYDROPHILIC MOLECULES AND UTILIZATIONS IN COSMETICS OR IN PHARMACY COLETICA (FR) 1995-02-15 EP claimed
WO-1993022370-A1 UNDECYLENIC ACID DERIVATIVES WITH HYDROPHILIC MOLECULES AND UTILIZATIONS IN COSMETICS OR IN PHARMACY COLETICA (FR) 1993-11-11 WO claimed
EP-0237398-B1 USE OF BIOLOGICALLY ACTIVE POLYPEPTIDES AND COMPOSITIONS CONTAINING THEM LVMH RECHERCHE (FR) 1992-07-01 EP claimed
EP-0143809-B1 METHOD FOR OBTAINING HUMAN HEPATOCYTES CULTURES, CULTURES OBTAINED THEREBY AND BIOLOGICAL AND BIOCHEMICAL APPLICATIONS THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1989-01-18 EP claimed
EP-0237398-A1 Use of biologically active polypeptides and compositions containing them LVMH RECHERCHE (FR) 1987-09-16 EP claimed
EP-0143809-A1 METHOD FOR OBTAINING HUMAN HEPATOCYTES CULTURES, CULTURES OBTAINED THEREBY AND BIOLOGICAL AND BIOCHEMICAL APPLICATIONS THEREOF. INST NAT SANTE RECH MED (FR) 1985-06-12 EP claimed
WO-1984004325-A1 METHOD FOR OBTAINING HUMAN HEPATOCYTES CULTURES, CULTURES OBTAINED THEREBY AND BIOLOGICAL AND BIOCHEMICAL APPLICATIONS THEREOF INST NAT SANTE RECH MED (FR) 1984-11-08 WO claimed
US-3945746-A Grating structure for roadway storm drain inlets and the like MARYLAND GRADING AND FABRICATING COMPANY, INC. (US) 1976-03-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388939-A1 RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF DBH, DDT, COMT DRD2 989/4885DRD1 1205/4885BCHE 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.